WallStSmart

Newmont Goldcorp Corp (NEM)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Newmont Goldcorp Corp generates 675% more annual revenue ($24.97B vs $3.22B). NEM leads profitability with a 33.9% profit margin vs 16.9%. NEM appears more attractively valued with a PEG of 2.78. NEM earns a higher WallStSmart Score of 78/100 (B+).

NEM

Strong Buy

78

out of 100

Grade: B+

Growth: 10.0Profit: 9.5Value: 4.0Quality: 8.0
Piotroski: 6/9Altman Z: 2.04

WST

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 8.0Value: 2.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NEMSignificantly Overvalued (-81.0%)

Margin of Safety

-81.0%

Fair Value

$68.86

Current Price

$116.51

$47.65 premium

UndervaluedFair: $68.86Overvalued
WSTSignificantly Overvalued (-32.4%)

Margin of Safety

-32.4%

Fair Value

$185.95

Current Price

$325.92

$139.97 premium

UndervaluedFair: $185.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NEM6 strengths · Avg: 9.8/10
Profit MarginProfitability
33.9%10/10

Keeps 34 of every $100 in revenue as profit

Operating MarginProfitability
61.4%10/10

Strong operational efficiency at 61.4%

Revenue GrowthGrowth
45.8%10/10

Revenue surging 45.8% year-over-year

EPS GrowthGrowth
78.6%10/10

Earnings expanding 78.6% YoY

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Market CapQuality
$124.38B9/10

Large-cap with strong market position

WST4 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

NEM1 concerns · Avg: 2.0/10
PEG RatioValuation
2.782/10

Expensive relative to growth rate

WST2 concerns · Avg: 2.0/10
PEG RatioValuation
2.892/10

Expensive relative to growth rate

P/E RatioValuation
41.8x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : NEM

The strongest argument for NEM centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 33.9% and operating margin at 61.4%. Revenue growth of 45.8% demonstrates continued momentum.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : NEM

The primary concerns for NEM are PEG Ratio.

Bear Case : WST

The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.

Key Dynamics to Monitor

WST carries more volatility with a beta of 1.17 — expect wider price swings.

NEM is growing revenue faster at 45.8% — sustainability is the question.

NEM generates stronger free cash flow (3.1B), providing more financial flexibility.

Monitor GOLD industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NEM scores higher overall (78/100 vs 67/100), backed by strong 33.9% margins and 45.8% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Newmont Goldcorp Corp

BASIC MATERIALS · GOLD · USA

Newmont Corporation, based in Greenwood Village, Colorado, United States, is one of the largest gold mining companies in the world.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?